Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission

Trial Profile

Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 May 2019 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.
    • 18 Dec 2018 Planned End Date changed from 1 Nov 2023 to 1 Nov 2022.
    • 04 Dec 2018 Results assessing safety and tolerability of lenalidomide presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top